Skip to content

Nutrition Impact on PRGF Treatment for Tendinopathy

Nutrition as a Risk Factor and Predictor of Treatment Outcome With Plasma Rich Growth Factors for Shoulder Tendinopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06536582
Acronym
NUTRITENDON
Enrollment
52
Registered
2024-08-05
Start date
2024-02-15
Completion date
2027-02-15
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Alterations, Shoulder Tendinopathy

Keywords

nutritional status, responder and non-responder patients, orthobiologics, Platelet rich growth factors

Brief summary

Given the close correlation reported in the literature between onset and progression of tendon pathology in subjects affected by the alteration of metabolic disorders such as obesity, diabetes mellitus and lipidic metabolic alterations, with the present study the association between the nutritional state, metabolic profile and clinical outcome of patients following treatment with blood-derived orthobiological for shoulder tendinopathies will be evaluated. The primary aim of this study is to identify the proportion of tendinopatic patients responsive and non-responsive to treatment with Platelet rich growth factors PRGF at six months follow up and the correlation with their nutritional status.

Detailed description

This is a single-center, observational study with an additional procedure (extra blood sampling routine, food questionnaires, anthropometric measurements for the evaluation of nutritional status), prospective, uncontrolled. Male and female patients, between 18 and 70 years old suffering from tendinopathy of the shoulder who undergo conservative regenerative medicine procedures with autologous PRGF material at the IRCCS Galeazzi-Sant'Ambrogio Hospital of Milan and participants in the observational study Use of Patient- Reported Outcome Measures (PROMs), objective clinical assessments and biomolecular technologies for monitoring patients undergoing treatments regenerative medicine \[REGAIN\] will be enrolled for this study. 46 patients will be needed: 1. 23 subjects with body mass index (BMI) between 18.5 and 25 therefore considered normal weight, who undergo treatment with PRGF; 2. 23 subjects with BMI values that exceed the considered range normal weight, therefore with BMI\>25, who undergo the PRGF treatment. The general aim of the present study is to evaluate the correlation between the nutritional status of patients, the characteristics of the orthobiological product used for the treatment of shoulder tendon pathology and clinical outcomes after one-step conservative regenerative medicine treatment with PRGF in order to identify the ideal nutritional conditions to obtain the best clinical outcome from this type of treatment. The primary objective of this study is to identify the proportion of tendinopatic patients responsive and non-responsive to treatment with orthobiological Platelet rich growth factors PRGF at six month follow up and the correlation with their nutritional status. To this end, responsive patients and non-responsive will be identified on the basis of the results of the VAS, ASES, Quick Dash, SPADI, WOOS scores, and Work index. The secondary objectives of the study will be: 1\) to Identify the proportion of responsive and non-responsive patients presenting shoulder tendinopathy to treatment with orthobiological Platelet rich growth factors PRGF at two and twelve months follow up and the correlation with their nutritional status. For this purpose, responsive and non-responsive patients will be identified on the basis of the results of the VAS, ASES, Quick Dash, SPADI scores, WOOS, and Work index. Characterization of the PRGF product used for the treatment of each patient that will occur by qualitative and quantitative analysis of the content in extracellular vesicles, analysis of a panel of cytokines, chemokines and growth factors linked to inflammation and correlated to the state nutritional information of patients (e.g. resistin, P-selectin, interleukins etc.).

Interventions

BIOLOGICALPlatelet rich growth factor injection (autologous product)

All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.

Sponsors

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female * Age ≥18 years and ≤ 70 years * Patients presenting shoulder tendinopathy * Signing of the Informed Consent of the Regain observational study * Signature of informed consent of the present study.

Exclusion criteria

* Pregnancy (ascertained by self-declaration), breastfeeding * Inability to follow the study protocol * Heart, kidney, oncological disease * Neuropsychiatric disease * Other conditions that, at the discretion of the investigator or physician, exclude enrollement

Design outcomes

Primary

MeasureTime frameDescription
Anthropometric measurement: suprailiac folds measurement0-24 monthssuprailiac folds measurement (mm)
Identification of nutritional status of responder and non-responder patients: gamma GT0-24 monthsGamma GT: U/l
Identification of nutritional status of responder and non-responder patients: calcium0-24 monthsCalcium: mg/dl
Identification of nutritional status of responder and non-responder patients:0-24 monthsC reactive protein: (mg/dl)
Identification of nutritional status of responder and non-responder patients: thyroid stimulating hormone (TSH)0-24 monthsthyroid stimulating hormone (TSH): uIU/ml
Identification of nutritional status of responder and non-responder patients: Insulin0-24 monthsInsulin: uU/ml
Identification of nutritional status of responder and non-responder patients: Folates0-24 monthsFolates (ng/ml)
Identification of nutritional status of responder and non-responder patients: vitamin B 120-24 monthsVitamin B 12 (pg/ml)
Anthropometric measurement: weight0-24 monthsweight (kg) measurement
Anthropometric measurement: height0-24 monthsheight (m) measurement
Anthropometric measurement: waist circumference0-24 monthswaist circumference (cm) measurement
Anthropometric measurement: arm circumference measurements0-24 monthsarm circumference measurements (cm)
Anthropometric measurement: biceps folds measurement0-24 monthsbiceps folds measurement (mm)
Anthropometric measurement: triceps folds measurement0-24 monthstriceps folds measurement (mm)
Anthropometric measurement: subscapular folds measurement0-24 monthssubscapular folds measurement (mm)
Identification of nutritional status of responder and non-responder patients: urea0-24 monthsUrea: mg/dl
Identification of nutritional status of responder and non-responder patients: creatinine0-24 monthsCreatinine: mg/dl
Identification of nutritional status of responder and non-responder patients: siderosis0-24 monthssiderosis: ug/dl
Identification of nutritional status of responder and non-responder patients: tryglicerides0-24 monthstryglicerides (mg/dl)
Identification of nutritional status of responder and non-responder patients: Vitamin D (25 OH)0-24 monthsVitamin D (25 OH): ng/ml
Identification of nutritional status of responder and non-responder patients: ferritin0-24 monthsFerritin (ng/ml)
Identification of nutritional status of responder and non-responder patients: Hemoglobin A1C (HbA1c)0-24 monthsHemoglobin A1C (HbA1c): mmol/mol
Responder and non-responder patient identification at 6 months follow-up.0-24 monthsThe primary objective of this study is to identify the proportion of responder and non-responder patients with shoulder tendinopathy to treatment with orthobiological Platelet rich growth factors PRGF at six month follow up. Responsive and non-responsive patients will be identified on the basis of the results of the VAS, ASES, Quick Dash, SPADI, WOOS scores, and Work index.
Identification of nutritional status of responder and non-responder patients: complete blood count0-24 monthsComplete blood count (cell number/dl)
Identification of nutritional status of responder and non-responder patients: blood glucose0-24 monthsBlood glucose (mg/dl)
Identification of nutritional status of responder and non-responder patients: cholesterol0-24 monthsCholesterol (mg/dl)
Identification of nutritional status of responder and non-responder patients: Cholesterol HDL0-24 monthsCholesterol HDL (mg/dl)
Identification of nutritional status of responder and non-responder patients: Glutamate-oxaloacetate transaminase0-24 monthsGlutamate-oxaloacetate transaminase: (U/l)
Identification of nutritional status of responder and non-responder patients: Glutamate-pyruvate transaminase0-24 monthsGlutamate-pyruvate transaminase: (U/l)

Secondary

MeasureTime frameDescription
The PRGF product used for the treatment of each patient will be characterizated: extracellular vesicles marker quantification24-26 monthsIdentification of extracellular vesicles markers: Arbitrary Fluorescence Unit
The PRGF product used for the treatment of each patient will be characterizated- quantitative analysis of cytokines: CXCL824-26 monthsQuantitative analysis of cytokines (CXCL8): pg/ml
The PRGF product used for the treatment of each patient will be characterizated- quantitative analysis of growth factors: G-CSF24-26 monthsQuantitative analysis of growth factors: G-CSF (pg/ml)
The PRGF product used for the treatment of each patient will be characterizated- quantitative analysis of resistin24-26 monthsQuantitative analysis of resistin: pg/ml
The PRGF product used for the treatment of each patient will be characterizated- quantitative analysis of P-selectin24-26 monthsQuantitative analysis of P-selectin: pg/ml
Responder and non-responder patient identification at 2 months follow-up.2-26 monthsThe secondary objectives of the study will be: to Identify the proportion of patients with shoulder tendinopathy responsive and non-responsive to treatment with orthobiological Platelet rich growth factors PRGF at two months follow up. For this purpose, responsive and non-responsive patients will be identified on the basis of the results of the VAS, ASES, Quick Dash, SPADI scores, WOOS, and Work index.
Responder and non-responder patient identification at 12 months follow-up.12-36 monthsThe secondary objectives of the study will be: to Identify the proportion of patients with shoulder tendinopathy responsive and non-responsive to treatment with orthobiological Platelet rich growth factors PRGF at twelve months follow up. For this purpose, responsive and non-responsive patients will be identified on the basis of the results of the VAS, ASES, Quick Dash, SPADI scores, WOOS, and Work index.
The Platelet rich growth factors PRGF product used for the treatment of each patient will be characterizated: extracellular vesicles count24-26 monthsextracellular vesicles count: number/ml

Other

MeasureTime frameDescription
VAS2-36 monthsVAS: Visual analogue scales for grading of pain. The VAS ranges from 0 (no pain) to 10 (worst pain) ((consists of a 10 cm line with 10 mm (0.01 cm) to each point of the scale and two end-points representing no pain and worst possible pain, where 0 = no pain, 1-3 = mild, 4-6 = moderate and 7-10 = severe pain))
Quick Dash Score2-36 monthsQuick Dash (Disabilities of Arm, Shoulder and Hand) score. The possible score ranges from 0 to 100 points. 0 points represent a complete, unrestricted function of the upper extremities, while 100 points represent the greatest possible functional impairment.
SPADI scores2-36 monthsSPADI (Shoulder Pain and Disability Index) scores. It evaluates pain and functional activities. Pain scale: 0 = no pain and 10 = the worst pain imaginable. Disability scale: 0 = no difficulty and 10 = so difficult it requires help. The means of the two subscales are averaged to produce a total score ranging from 0 (best) to 100 (worst).
WOOS Index2-36 monthsWOOS (Western Ontario Osteoarthritis of the Shoulder) index. 0% is the worst possible result and 100% is the best possible results.
WORC Index2-36 monthsThe WORC (Western Ontario Rotator Cuff) Index, is a disease-specific quality of life questionnaire, evaluating the change in symptoms and functional ability, specific to a RC tendinopathy. Total final WORC scores can, therefore, range from 0% (lowest functional status level) to 100% (the highest functional status)
ASES SCORE2-36 monthsASES (American Shoulder and Elbow Surgeons) Score: ASES score ranges from 0 to 100, with 0 the lowest level of function and 100 the highest level of function

Countries

Italy

Contacts

Primary ContactPaola De Luca, PhD
deluca.paola@grupposandonato.it+39 3921385179
Backup ContactMichela Taiana, PhD
michelamaria.taiana@grupposandonato.it+39 3335952857

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026